Cargando…

Late follow‐up of genital and ophthalmologic chronic graft‐vs‐host disease in females after allogeneic stem cell transplantation

INTRODUCTION: Genital chronic graft‐vs‐host disease (cGvHD) is a common late effect after allogeneic stem cell transplantation. In a previous cross‐sectional study, prevalence, signs and symptoms of genital and extra‐genital cGvHD were accounted for in a cohort of 42 women. Classifications of cGvHD...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith Knutsson, Eva, Nicklasson, Malin, Björk, Yvonne, Stenberg, Kristina, Sundfeldt, Karin, Brune, Mats
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564436/
https://www.ncbi.nlm.nih.gov/pubmed/34962288
http://dx.doi.org/10.1111/aogs.14308
_version_ 1784808643297804288
author Smith Knutsson, Eva
Nicklasson, Malin
Björk, Yvonne
Stenberg, Kristina
Sundfeldt, Karin
Brune, Mats
author_facet Smith Knutsson, Eva
Nicklasson, Malin
Björk, Yvonne
Stenberg, Kristina
Sundfeldt, Karin
Brune, Mats
author_sort Smith Knutsson, Eva
collection PubMed
description INTRODUCTION: Genital chronic graft‐vs‐host disease (cGvHD) is a common late effect after allogeneic stem cell transplantation. In a previous cross‐sectional study, prevalence, signs and symptoms of genital and extra‐genital cGvHD were accounted for in a cohort of 42 women. Classifications of cGvHD were performed as per the National Institutes of Health (NIH) 2005 criteria. In this follow‐up study on surviving women, the aim was to assess genital and extra‐genital cGvHD status after long period of time. Our hypothesis was that signs and symptoms of cGvHD alleviate over time. MATERIAL AND METHODS: All surviving women (n = 38) were re‐examined by an ophthalmologist, a gynecologist and a hematologist. Signs and symptoms were classified according to the NIH 2014 criteria. Clinical scorings of affected organs were combined for estimating global score of cGvHD. To make possible comparisons between the two studies, data from the original study were re‐classified as per the NIH 2014 criteria, and the four dead women were excluded. The same questionnaires were completed. Cervical smear, human papilloma virus test and vulvar photo‐documentation were performed. RESULTS: Median time after original study was 8.4 (5.8–12) years and after transplant 14.5 (10–19.3) years. The prevalence of genital cGvHD was similar in the original (50%) and follow‐up (58%) studies (p = 0.646) as well as extra‐genital cGvHD. Systemic corticosteroid treatment of cGvHD was ongoing in 34% and 29%, respectively (p = 0.805). Ocular cGvHD was found in 24 of 37 examined women (65%) in the follow‐up study. Genital cGvHD had disappeared in three women and developed in two women 5–12 and 9–17 years, respectively, after transplantation. The severity of global cGvHD changed over time in 14 women, but was the same on group level (p = 0.345). Atrophic mucous membranes as in estrogen deficiency were seen in 66%. Three women had human papilloma virus genotypes associated with the risk of developing cervical cancer. CONCLUSIONS: Chronic GvHD did not alleviate over time. Allotransplanted women require early and continuous life‐long contact with a gynecologist and an ophthalmologist for the detection of cGvHD. Specific attention should be given to the need for local estrogen and the risk of genital epithelial malignancies.
format Online
Article
Text
id pubmed-9564436
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95644362022-12-06 Late follow‐up of genital and ophthalmologic chronic graft‐vs‐host disease in females after allogeneic stem cell transplantation Smith Knutsson, Eva Nicklasson, Malin Björk, Yvonne Stenberg, Kristina Sundfeldt, Karin Brune, Mats Acta Obstet Gynecol Scand Other INTRODUCTION: Genital chronic graft‐vs‐host disease (cGvHD) is a common late effect after allogeneic stem cell transplantation. In a previous cross‐sectional study, prevalence, signs and symptoms of genital and extra‐genital cGvHD were accounted for in a cohort of 42 women. Classifications of cGvHD were performed as per the National Institutes of Health (NIH) 2005 criteria. In this follow‐up study on surviving women, the aim was to assess genital and extra‐genital cGvHD status after long period of time. Our hypothesis was that signs and symptoms of cGvHD alleviate over time. MATERIAL AND METHODS: All surviving women (n = 38) were re‐examined by an ophthalmologist, a gynecologist and a hematologist. Signs and symptoms were classified according to the NIH 2014 criteria. Clinical scorings of affected organs were combined for estimating global score of cGvHD. To make possible comparisons between the two studies, data from the original study were re‐classified as per the NIH 2014 criteria, and the four dead women were excluded. The same questionnaires were completed. Cervical smear, human papilloma virus test and vulvar photo‐documentation were performed. RESULTS: Median time after original study was 8.4 (5.8–12) years and after transplant 14.5 (10–19.3) years. The prevalence of genital cGvHD was similar in the original (50%) and follow‐up (58%) studies (p = 0.646) as well as extra‐genital cGvHD. Systemic corticosteroid treatment of cGvHD was ongoing in 34% and 29%, respectively (p = 0.805). Ocular cGvHD was found in 24 of 37 examined women (65%) in the follow‐up study. Genital cGvHD had disappeared in three women and developed in two women 5–12 and 9–17 years, respectively, after transplantation. The severity of global cGvHD changed over time in 14 women, but was the same on group level (p = 0.345). Atrophic mucous membranes as in estrogen deficiency were seen in 66%. Three women had human papilloma virus genotypes associated with the risk of developing cervical cancer. CONCLUSIONS: Chronic GvHD did not alleviate over time. Allotransplanted women require early and continuous life‐long contact with a gynecologist and an ophthalmologist for the detection of cGvHD. Specific attention should be given to the need for local estrogen and the risk of genital epithelial malignancies. John Wiley and Sons Inc. 2021-12-28 /pmc/articles/PMC9564436/ /pubmed/34962288 http://dx.doi.org/10.1111/aogs.14308 Text en © 2021 The Authors. Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG). https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Other
Smith Knutsson, Eva
Nicklasson, Malin
Björk, Yvonne
Stenberg, Kristina
Sundfeldt, Karin
Brune, Mats
Late follow‐up of genital and ophthalmologic chronic graft‐vs‐host disease in females after allogeneic stem cell transplantation
title Late follow‐up of genital and ophthalmologic chronic graft‐vs‐host disease in females after allogeneic stem cell transplantation
title_full Late follow‐up of genital and ophthalmologic chronic graft‐vs‐host disease in females after allogeneic stem cell transplantation
title_fullStr Late follow‐up of genital and ophthalmologic chronic graft‐vs‐host disease in females after allogeneic stem cell transplantation
title_full_unstemmed Late follow‐up of genital and ophthalmologic chronic graft‐vs‐host disease in females after allogeneic stem cell transplantation
title_short Late follow‐up of genital and ophthalmologic chronic graft‐vs‐host disease in females after allogeneic stem cell transplantation
title_sort late follow‐up of genital and ophthalmologic chronic graft‐vs‐host disease in females after allogeneic stem cell transplantation
topic Other
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564436/
https://www.ncbi.nlm.nih.gov/pubmed/34962288
http://dx.doi.org/10.1111/aogs.14308
work_keys_str_mv AT smithknutssoneva latefollowupofgenitalandophthalmologicchronicgraftvshostdiseaseinfemalesafterallogeneicstemcelltransplantation
AT nicklassonmalin latefollowupofgenitalandophthalmologicchronicgraftvshostdiseaseinfemalesafterallogeneicstemcelltransplantation
AT bjorkyvonne latefollowupofgenitalandophthalmologicchronicgraftvshostdiseaseinfemalesafterallogeneicstemcelltransplantation
AT stenbergkristina latefollowupofgenitalandophthalmologicchronicgraftvshostdiseaseinfemalesafterallogeneicstemcelltransplantation
AT sundfeldtkarin latefollowupofgenitalandophthalmologicchronicgraftvshostdiseaseinfemalesafterallogeneicstemcelltransplantation
AT brunemats latefollowupofgenitalandophthalmologicchronicgraftvshostdiseaseinfemalesafterallogeneicstemcelltransplantation